12th ANNUAL SCIENTIFIC SYMPOSIUM
A CME/CNE – Certified Conference

BRCA1, BRCA2 and Beyond: An Update on Hereditary Cancer

Keynote Speaker and Basser Global Prize Awardee: Kenneth Offit, MD, MPH

MONDAY, MAY 13 – TUESDAY, MAY 14, 2024

Smilow Center for Translational Research Auditorium/Commons
(enter through Perelman Center for Advanced Medicine)
Program Overview

This hybrid symposium is designed to educate researchers, scientists, and health care providers in cancer genetics by presenting cutting-edge data from renowned researchers and clinicians. This symposium will provide new information on progress in cancer screening and prevention, as well as ongoing work in targeted therapy for BRCA1/2 and other mutation carriers through a series of lectures and panel discussions.

PROGRAM OBJECTIVES

At the completion of this symposium, attendees should be able to:

• Discuss new research on the genetic epidemiology of BRCA1/2 and other homologous recombination deficiency (HRD) genes.

• Describe current ethical, legal and social issues associated with carrying a BRCA1/2 mutation.

• Review new approaches to screening and prevention of hereditary breast, ovarian, pancreatic and prostate cancer.

• Discuss new advances in treatment for mutation carriers of BRCA1/2 and other known cancer susceptibility genes.

WHO SHOULD ATTEND

Healthcare providers including medical oncology, surgical oncology, gynecology oncology, OB-GYN, genetic counselors, primary care physicians, physician assistants and nurses/nurse practitioners who are interested in the genetics of BRCA1/2 related cancers.

The symposium is sponsored in part by a generous gift from Margaret I. Cuomo and Howard Maier.
The Basser Center is honored to announce Kenneth Offit, MD, MPH of Memorial Sloan Kettering Cancer Center, is the recipient of the 12th annual Basser Global Prize. Dr. Offit is the Robert and Kate Niehaus Chair in Inherited Cancer Genomics and serves as Chief of the Clinical Genetics Service at MSKCC. Dr. Offit received his MD and MPH from Harvard University. Dr. Offit’s work identified the most common mutation associated with an increased risk of breast, ovarian, and prostate cancer among individuals of Ashkenazi Jewish ancestry. He also published the first prospective series describing the outcome of preventive ovarian surgery and screening in women at hereditary risk for breast and ovarian cancer.

Dr. Offit founded one of the first clinical cancer genetics services in 1992 and led the first American Society of Clinical Oncology policy statement after the identification of the BRCA1 and BRCA2 genes. His ongoing research includes leading an implementation study, funded by the National Institutes of Health, to pilot health dissemination of genomic information.
Susan Domchek is the Basser Professor in Oncology at the Perelman School of Medicine of the University of Pennsylvania. She serves as Executive Director of the Basser Center for BRCA at the Abramson Cancer Center and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Center. Her work focuses on the genetic evaluation and medical management of individuals with inherited risk factors for cancer. Dr. Domchek is particularly interested in developing new cancer therapies, such as PARP inhibitors, for patients with genetic risk factors. An elected member of the National Academy of Medicine, Dr. Domchek is also a significant contributor to the oncology literature. She has authored/co-authored more than 400 articles appearing in scholarly journals including the New England Journal of Medicine, the Journal of the American Medical Association and the Journal of Clinical Oncology, among others.
SYMPOSIUM CO-ORGANIZERS

Ronald Drapkin, MD, PhD
Franklin Payne Associate Professor of Pathology in Obstetrics & Gynecology
Director, Penn Ovarian Cancer Research Center
Director of Gynecologic Cancer Research, Basser Center for BRCA

Dana Farengo Clark, MS, MS, LCGC
Senior Genetic Counselor
Mariann & Robert MacDonald Cancer Risk Evaluation Center
Basser Center for BRCA

Adam Fredo, PA-C
Physician Assistant
Medical Oncology
Penn Medicine

Roger Greenberg, MD, PhD
J. Samuel Staub, MD, Professor, Department of Cancer Biology
Director, Penn Center for Genome Integrity (PCGI)
Director of Basic Science, Basser Center for BRCA

Mosetta Harris, CRNP
Nurse Practitioner
Rena Rowan Breast Center
Penn Medicine

Katherine Nathanson, MD
Pearl Basser Professor of BRCA-Related Research
Deputy Director, Abramson Cancer Center
Director of Genetics, Basser Center for BRCA

PENN MEDICINE FACULTY

Jessica Ebrahimzadeh, MS, LCGC
Genetic Counselor
Mariann & Robert MacDonald Cancer Risk Evaluation Center
Basser Center for BRCA

Derek Mann, MS, LCGC
Genetic Counselor
Mariann & Robert MacDonald Cancer Risk Evaluation Center
Basser Center for BRCA

Ben Stanger, MD, PhD
Hanna Wise Professor in Cancer Research
Director, Penn Pancreatic Cancer Research Center

GUEST SPEAKERS

Jennifer Guerriero, PhD
Assistant Professor, Harvard Medical School
Lead Investigator, Brigham and Women’s Hospital Breast Cancer Program, Dana-Farber/Harvard Cancer Center
Harvard Immunology, Harvard Medical School

Jada Hamilton, PhD, MPH
Co-Director, Genomics, Risk & Health Decision-Making Laboratory
Associate Attending Psychologist, Department of Psychiatry & Behavioral Sciences
Clinical Genetics Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Kai Kessenbrock, PhD  
Associate Professor, Biological Chemistry  
Chao Family Comprehensive Cancer Center  
University of California, Irvine

Hendrik Messal, PhD  
Senior Postdoctoral Researcher  
The Netherlands Cancer Institute

Kenneth Olive, PhD  
Associate Professor of Medicine  
Columbia University Irving Medical Center

John Richardson  
Director of Policy and Government Affairs  
National Society of Genetic Counselors (NSGC)

Mark Robson, MD  
Chief, Breast Medicine Service  
Clinic Director, Clinical Genetics Service  
Memorial Sloan Kettering Cancer Center

Sven Rottenberg, DVM, PhD, Dipl. ECVP  
Department Chair, Department of Infectious Diseases and Pathobiology (DIP), Vetsuisse Faculty  
University of Bern

Violeta Serra, PhD  
Group Leader, Experimental Therapeutics Group  
Miguel Servet Investigator  
Vall D’Hebron Institute of Oncology, Barcelona Spain

Clare Turnbull, MD, PhD, FRCP, FRCPath, MFPH  
Professor of Translational Cancer Genetics | Institute of Cancer Research  
NHS Consultant in Clinical Cancer Genetics (Honorary) | Royal Marsden NHS Foundation Trust  
Consultant in Public Health Medicine (Honorary) | Public Health England

Laura Valle, PhD  
Principal Investigator  
Hereditary Cancer Program  
Catalan Institute of Oncology, IDIBELL  
Barcelona, Spain

Gilbert Welch, MD, MPH  
Center for Surgery and Public Health  
Brigham and Women’s Hospital

Gerburg Wulf, MD, PhD  
Associate Professor of Medicine, Harvard Medical School  
Beth Israel Deaconess Medical Center  
Dana Farber/Harvard Cancer Center

Dmitriy Zamarin, MD, PhD  
Associate Professor  
Section Head, Gynecologic Medical Oncology  
Precision Immunology Institute  
Icahn School of Medicine at Mount Sinai
7:30-8:15am  Registration
8:15-8:30am  Welcome

Morning Session
8:30-9:00am  Kai Kessenbrock, PhD
Understanding the role of the microenvironment in BRCA1-driven breast tumorigenesis

9:00-9:30am  Ronald Drapkin, MD, PhD
Developing a pre-cancer atlas for cancer interception

9:30-10:00am  Kenneth Olive, PhD
Targeting and preventing pancreatic cancer BRCA2-mutant mouse models

10:00-10:30am  BREAK

10:30-11:00am  Jennifer Guerriero, PhD
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer

11:00-11:30am  Hendrik Messal, PhD
A high burden of abnormal cell behavior in disease-free human breasts

11:30-12:00pm  Roger Greenberg, MD, PhD
Targeting homologous recombination deficient cancers

12:00-1:15pm  LUNCH
**Afternoon Session**

1:15-1:45pm  
Ben Stanger, MD, PhD  
Personalized models and interception strategies for pancreatic cancer

1:45-2:15pm  
Dmitriy Zamarin, MD, PhD  
Overcoming immune heterogeneity in ovarian cancer

2:15-2:45pm  
Violeta Serra, PhD  
HRD beyond BRCA1/2 and the need of functional biomarkers

2:45-3:15pm  
Sven Rottenberg, DVM, PhD, Dipl. ECVP  
Mechanisms of genetic reversion-independent chemoresistance in BRCA1/2-mutated tumors

3:15-3:45pm  
Gerburg Wulf, MD, PhD  
A short course of olaparib combinations for the prevention of BRCA1-related breast cancer

End of accredited portion

4:00-5:00pm  
**Poster Session**
7:30-8:15am  Registration
8:15-8:30am  Welcome

Morning Session
8:30-9:00am  Gilbert Welch, MD
Multicancer early detection screening: Challenges posed by birds, rabbits, and turtles

9:00-9:30am  Clare Turnbull, MD, PhD, FRCP, FRCPath, MFPH
Population genomic risk stratification to inform cancer screening

9:30-10:00am  Mark Robson, MD
Update on treatment of hereditary breast cancer

10:00-10:30am  BREAK

10:30-11:00am  Laura Valle, PhD
APC I1307K and cancer risk: Recommendations of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) for classification of the variant, cancer screening, and predictive testing

11:00-11:30am  Katherine Nathanson, MD
Comprehensive analysis of the landscape of reversion mutations in HR genes

11:30-12:00pm  Jada Hamilton, PhD, MPH
Implications of polygenic risk scores for risk-reducing mastectomy decision-making experiences among BRCA1/2 carriers

12:00-1:15pm  LUNCH
Afternoon Session

1:15-1:45pm
John Richardson
Genetic Counselor advocacy update: State licensure and Medicare provider status

1:45-2:15pm
Derek Mann, MS, LCGC
Year in review: Updates and trends in hereditary cancer genetic counseling

2:15-3:00pm
Case Panel moderated by Susan Domchek, MD with:
Jessica Ebrahimzadeh MS, LCGC, Kenneth Offit, MD, MPH and Mark Robson, MD

3:00-3:15pm
BREAK

3:15-4:30pm
Global Prize Presentation and Keynote
Kenneth Offit, MD, MPH
BRCA at 30: Phenotype, penetrance and populations

4:30-5:00pm
Wrap Up and Evaluations
End of accredited portion

5:00-6:00pm
Breakthroughs & Discoveries Panel moderated by Jill Werman Harris:
featuring Susan Domchek, MD, Kenneth Offit, MD, MPH, Gilbert Welch, MD, Clare Turnbull, MD, PhD, FRCP, FRCPath, MFPH

This lay session is open to the public.
Registration Information

This conference is FREE but we strongly recommend registration. Registration is required for continuing education credits.

ACCREDITATION AND DESIGNATION OF CREDIT
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Nurse/Nurse Practitioners
The program will award 12.5 NCPD hours

Physicians
Penn Medicine designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 12.5 Category 1 credits for completing this activity.

Genetic Counselors
This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

CANCELLATION POLICY
The University reserves the right to cancel or postpone any activity due to unforeseen circumstances. In the event of cancellation or postponement, the University will not be responsible for related costs or expenses to participants, including cancellation fees assessed by hotels, airlines, or travel agencies.

SERVICES FOR THE DISABLED
If special arrangements are required for an individual with a disability to attend this meeting, please contact basserinfo@pennmedicine.upenn.edu by April 29, 2024.

SPECIAL REQUESTS
If special requests for food or other logistics are required, contact basserinfo@pennmedicine.upenn.edu by April 29, 2024.

NONDISCRIMINATION STATEMENT
The University of Pennsylvania values diversity and seeks talented students, faculty and staff from diverse backgrounds. The University of Pennsylvania does not discriminate on the basis of race, sex, sexual orientation, gender identity, religion, color, national or ethnic origin, age, disability, or status as a Vietnam Era Veteran or disabled veteran in the administration of educational policies, programs or activities; admissions policies; scholarship and loan awards; athletic, or other University administered programs or employment. Questions or complaints regarding this policy should be directed to: Executive Director, Office of Affirmative Action and Equal Opportunity Programs, 3600 Chestnut Street, Sansom Place East, Suite 228, Philadelphia, PA 19104-6106 or 215.898.6993 (Voice) or 215.898.7803 (TDD).
Visiting Information

HOTEL

A block of rooms has been reserved at the Sheraton Philadelphia University City Hotel at a special group rate of $199 per night.

Rooms must be reserved by April 13, 2024 to take advantage of the group rate.

RESERVE YOUR ROOM
COVID GUIDELINES
Penn Medicine’s COVID guidelines for visitors to campus can be found here: https://www.pennmedicine.org/coronavirus/visitation-policy-and-guidelines

PARKING
Parking will not be available on the medical campus, but public self-pay parking lots available in the University City vicinity can be found at:

- Drexel University Parking Lot – 34th and Market Streets
- University of Pennsylvania Parking Lot – 34th and Chestnut Streets
- University of Pennsylvania Parking Lot - 38th and Walnut Streets

For more information, visit http://cms.business-services.upenn.edu/parking/

PUBLIC TRANSPORTATION
The SEPTA Penn Medicine Station (formerly University City Station) is within walking distance of the medical campus. For more information, visit www.septa.org.
The Basser Center for BRCA is the first comprehensive center for the research, treatment and prevention of BRCA-related cancers. Devoted to advancing care for people affected by BRCA mutations, the Basser Center’s unique model provides funding for collaborative research, education and outreach programs around the world.

WE TAKE CANCER PERSONALLY.